Source:http://linkedlifedata.com/resource/pubmed/id/19385967
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2009-6-8
|
pubmed:abstractText |
Anthracycline-based chemotherapy represents a milestone in the treatment of breast cancer. We previously demonstrated in an in vitro model that cyclin E overexpression is associated with increased expression of manganese superoxide dismutase (MnSOD) and resistance to doxorubicin. In the present study, immunohistochemical expression of cyclin E and MnSOD was evaluated in 134 early breast cancer patients receiving adjuvant epirubicin-based chemotherapy regimens containing epirubicin. Both parameters were correlated with the available clinicopathological parameters and with the outcome of patients. Overexpression of cyclin E and MnSOD was detected in 46 (34.3%) and 56 (41.8%) patients, respectively, and expression levels of the two proteins were related. Disease-free and alive patients displayed a lower mean percentage of cyclin E-expressing cells than relapsed and dead patients, respectively. Kaplan-Meier survival analysis demonstrated a significant separation between high versus low cyclin E-expressing tumors in terms of overall survival (P = 0.038 by log-rank). Similar results were obtained considering the subset of node-negative patients separately. No significant relationship with patient outcome was observed for MnSOD expression levels. At multivariate analysis cyclin E failed to demonstrate an independent prognostic value. In conclusion, the results of the present study support previous evidence that increased cyclin E expression is associated with higher MnSOD expression levels and poorer outcome, at least as evaluated in terms of overall survival. Further studies are warranted to evaluate the usefulness of cyclin E as a prognostic marker to identify breast cancer patients at higher risk of death from the disease when treated with adjuvant anthracycline-based therapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin E,
http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Superoxide Dismutase
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1349-7006
|
pubmed:author |
pubmed-author:AmorosoDomenicoD,
pubmed-author:BevilacquaGenerosoG,
pubmed-author:CameriniAndreaA,
pubmed-author:CapodannoAlessandraA,
pubmed-author:CittadiniAchilleA,
pubmed-author:CollecchiPaolaP,
pubmed-author:GrazianiCristinaC,
pubmed-author:MasciulloValeriaV,
pubmed-author:MigaldiMarioM,
pubmed-author:RossiGiulioG,
pubmed-author:ScambiaGiovanniG,
pubmed-author:SgambatoAlessandroA
|
pubmed:issnType |
Electronic
|
pubmed:volume |
100
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1026-33
|
pubmed:meshHeading |
pubmed-meshheading:19385967-Adult,
pubmed-meshheading:19385967-Aged,
pubmed-meshheading:19385967-Antibiotics, Antineoplastic,
pubmed-meshheading:19385967-Breast Neoplasms,
pubmed-meshheading:19385967-Chemotherapy, Adjuvant,
pubmed-meshheading:19385967-Combined Modality Therapy,
pubmed-meshheading:19385967-Cyclin E,
pubmed-meshheading:19385967-Disease-Free Survival,
pubmed-meshheading:19385967-Epirubicin,
pubmed-meshheading:19385967-Female,
pubmed-meshheading:19385967-Humans,
pubmed-meshheading:19385967-Immunohistochemistry,
pubmed-meshheading:19385967-Middle Aged,
pubmed-meshheading:19385967-Receptors, Estrogen,
pubmed-meshheading:19385967-Receptors, Progesterone,
pubmed-meshheading:19385967-Superoxide Dismutase,
pubmed-meshheading:19385967-Survival Rate
|
pubmed:year |
2009
|
pubmed:articleTitle |
Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy.
|
pubmed:affiliation |
Giovanni XXIII Cancer Research Center, Catholic University of Sacred Heart, Rome, Italy. asgambato@rm.unicatt.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|